CN1274338C - Traditional Chinese medicine for treating aplastic anemia and its preparation process - Google Patents
Traditional Chinese medicine for treating aplastic anemia and its preparation process Download PDFInfo
- Publication number
- CN1274338C CN1274338C CNB031254667A CN03125466A CN1274338C CN 1274338 C CN1274338 C CN 1274338C CN B031254667 A CNB031254667 A CN B031254667A CN 03125466 A CN03125466 A CN 03125466A CN 1274338 C CN1274338 C CN 1274338C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- aplastic anemia
- treatment
- traditional chinese
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses traditional Chinese medicine for curing aplastic anemia and a preparation technology thereof. The traditional Chinese medicine is a medicament proportionally prepared from red ginseng tails, astragalus root, prepared rehmannia root, dodder seed, sliced cornus cervi, broil tortoise plastron, fructus lycii, psoralea fruit, cooked aconite and cassia bark. In the preparation technology of the present invention, the 10 kinds of traditional Chinese medicine raw materials are decocted for two times by being added with water, and filter solutions obtained through the two time decoction are combined; then, the filter solutions are concentrated, deposited by ethanol and refrigerated to a room temperature for becoming a pasty object; then, after being dried, the pasty object is sprayed with powder and is filled in a capsule for becoming a capsule preparation, or the pasty object is added with dextrin or starch for being prepared into a soft material; finally, the soft material is processed through sieving and drying for being prepared into powder preparation for infusion or being pressed into a tablet. The traditional Chinese medicine can regulate disturbance mediated by the immunity of human bodies, stimulate the restoration of the hematopoiesis function of the marrow of human bodies, and has an obvious effect on the cure of aplastic anemia. The traditional Chinese medicine has a good curative effect on symptoms, such as bone marrow depression, cytopenia, etc., caused by other refractory anemia and various reasons. Simultaneously, the traditional Chinese medicine nearly has no toxic or side effect, is safe and reliable, and has low cost.
Description
Technical field
The present invention relates to the Chinese herbal medicine is the kidney tonifying marrow facilitating medicament that feedstock production forms, and refers to a kind of Chinese medicine and preparation technology thereof who treats aplastic anemia particularly.
Background technology
Aplastic anemia has become very harmful blood system common disease as the hyperfunction disease of the secondary regulation and control of a kind of hemopoietic.They are many clinically based on chronic, protracted course of disease, and the treatment difficulty is high, does not still have ideal medicine so far, makes the clinicist quite feel thorny.Particularly in recent years along with the appearance of national house decoration upsurge, people are increasing with the probability that harmful chemical finishing material contacts, cause the sickness rate of China's aplastic anemia to increase year by year, and the trend that the patient becomes younger has appearred, therefore press for a kind of safe and reliable treatment new drug.
Domestic and international at present treatment to aplastic anemia, nothing more than following a few class medicine is arranged: one, androgen and cyclosporin are when for treating the most frequently used medicine of aplastic anemia now, but the two all has toxic and side effects in various degree, makes its clinical practice be subjected to very big restriction.Its two, cytokines such as GM-CSF, EPO, IL-3 begin to be used for aplastic anemia treatment in recent years, but its curative effect is not lasting, and cost an arm and a leg, be not the choice drug of treatment.They are three years old, Chinese patent drugs for treatment aplastic anemia, as promoting hemogenesis for aplastic anemia tablet common on the market, SHENGXUE WAN, FUFANG ZAOFAN WAN etc., but this type of Chinese patent medicine mainly has been the effect of YIN nourishing, pathogenic fire reducing, spleen reinforcing, the effect of benefit marrow hemopoietic is then relatively poor, so it can only improve patient's clinical symptoms mostly, clinical therapeutic efficacy is then not good enough, effective percentage only is 30～50%, and the patient still has to rely on Western medicine such as cyclosporin.
Summary of the invention
Purpose of the present invention will overcome above-mentioned the deficiencies in the prior art part exactly, and the Chinese medicine and the preparation technology thereof of a kind of safe and reliable, determined curative effect and treatment aplastic anemia with low cost is provided.By the kidney tonifying marrow facilitating Chinese medicine that this prepared forms, not only can regulate the immune-mediated disorder of human body, stimulate the recovery of human bone marrow's hemopoietic function, treatment aplastic anemia effect is remarkable, and does not almost have obvious toxic-side effects.
For achieving the above object, the present invention thinks according to China's theory of Chinese medical science and practice: the key of aplastic anemia morbidity is to suffer from a deficiency of the kidney, its essence is insufficiency of kidney-YANG, and with the effect of the useful marrow hemopoietic of the kidney invigorating ruling by law treatment aplastic anemia, its clinical effect is better than spleen reinforcing class and the clear Chinese medicine of growing class greatly.YIN-deficiency type aplastic anemia is converted into deficiency of yang type aplastic anemia, clinically just can alleviate.According to above-mentioned theory of Chinese medical science, with reference to modern pharmacological research, the present invention is from China's medicine treasure-house, filter out invigorating primordial QI, mend marrow, fill blood, the natural Chinese medicine of spleen reinforcing kidney, the body resistance strengthening and constitution consolidating, by the theory of Chinese medical science prescription, extract elite wherein, make its performance adjust immune-mediated disorder, releasing is to the inhibition of bone marrow hematogenesis, improve the level of IL-3, promote the propagation and the differentiation of hematopoietic stem, promote the endocrine hormone receptor affinity, and then the recovery of hemopoietic function, splendid to the chronic aplastic anemia effect.
The Chinese medicine of treatment aplastic anemia proposed by the invention is the medicament that is prepared from by following materials of weight proportions:
Leptoradix Ginseng Rubra 15～50 Radixs Astragali 5～30 Radix Rehmanniae Preparata 5～30
Semen Cuscutae 5～30 Cornu Cervi tablets 5～30 Carapax Et Plastrum Testudinis (processed) 5～30
Fructus Lycii 5～30 Fructus Psoraleaes 5～30 Radix Aconiti Lateralis Preparata 3～20
Cortex Cinnamomi 1～15.
The preferred weight proportioning of the raw material of preparation medicament of the present invention is:
Leptoradix Ginseng Rubra 20～40 Radixs Astragali 8～15 Radix Rehmanniae Preparata 8～15
Semen Cuscutae 8～15 Cornu Cervi tablets 8～15 Carapax Et Plastrum Testudinis (processed) 8～15
Fructus Lycii 8～15 Fructus Psoraleaes 8～15 Radix Aconiti Lateralis Preparata 5～10
Cortex Cinnamomi 1～8.
The optimum weight proportioning of the raw material of preparation medicament of the present invention is:
Leptoradix Ginseng Rubra 25 Radixs Astragali 8 Radix Rehmanniae Preparata 8
Semen Cuscutae 8 Cornu Cervi tablets 8 Carapax Et Plastrum Testudinis (processed) 8
Fructus Lycii 8 Fructus Psoraleaes 8 Radix Aconiti Lateralis Preparata 8
Cortex Cinnamomi 2.
Medicament of the present invention can be a said dosage form on any pharmaceutics, and what select for use usually is electuary, tablet or capsule.
The preparation technology of the Chinese medicine of treatment aplastic anemia of the present invention is: by above-mentioned weight proportion Leptoradix Ginseng Rubra, the Radix Astragali, Radix Rehmanniae Preparata, Semen Cuscutae, Cornu Cervi tablet, Carapax Et Plastrum Testudinis (processed), Fructus Lycii, Fructus Psoraleae, Radix Aconiti Lateralis Preparata, ten raw material of Chinese medicine of Cortex Cinnamomi are decocted with water twice, the decocting that at every turn adds 6～8 times of raw material weights boiled 30～60 minutes, merged filtrate twice.Concentrate then, precipitate with ethanol, be cooled to room temperature and become paste.Again paste is carried out dried, the fill of dusting after the adding appropriate amount of auxiliary materials becomes capsule.Or the dextrin or the starch that add 1～2 times of its weight in paste makes soft material, at last soft material sieved, drying, makes electuary or is pressed into tablet.
Basic research works such as clinical, the pharmacology of treatment aplastic anemia Chinese medicine of the present invention, toxicity, pharmacy are summarized as follows:
Completed clinical research is provided with two groups of identical matched groups of condition, and the result proves: basic healing, remission rate and the total effective rate of Chinese medicine preparation treatment group of the present invention all obviously is better than Western medicine " stanozolol " matched group.Observe the CD of kidney yang deficiency syndrome Patients with Aplastic Anemia simultaneously
3, CD
4/ CD
8Obviously reduce CD
8Obviously raise T
3, T
4, T, F significantly reduce, IL-2, IFN-γ, TNF-α significantly increase, sIL-2R, IL-3 obviously reduce, the essence of prompting kidney yang deficiency syndrome aplastic anemia is unbalance relevant with nerve--endocrine---immune system function.Kidney tonifying marrow facilitating Chinese medicine preparation of the present invention can be adjusted immune-mediated disorder on the one hand, improves CD
3, CD
4/ CD
8Ratio, reduce CD
8Quantity and activity, to remove the inhibition of disease to bone marrow hematogenesis.Can improve the sIL-2R level on the other hand, reduce the release of hemopoietic negative regulatory factors such as IL-2, IFN-γ, TNF-α.Can improve simultaneously the level of IL-3,, hemopoietic function of bone marrow be recovered to promote the propagation and the differentiation of hematopoietic stem.Experimentation shows: kidney tonifying marrow facilitating Chinese medicine preparation of the present invention can promote the growth of polytropism hemopoietic chief cell (CFU-S), red owner's cell (BFU-E) and grain owner's cell (CFU-C).Endocrine hormone especially androgen and hemopoietic has substantial connection, the metabolic endocrine hormone level of kidney yang deficiency syndrome aplastic anemia reflection function is obviously low, and after treatment by Chinese herbs of the present invention, can significantly go up, illustrate that this kidney tonifying marrow facilitating Chinese medicine preparation has the effect that promotes the hormone in vivo receptor affinity, helps the recovery of hemopoietic function.
Acute toxicological experiment records the LD of Chinese medicine preparation of the present invention
50＞190.75g/kg.It can improve the productive rate of immune-mediated property Induced Aplastic Anemia Mice bone marrow CFU-E, BFU-E, CFU-GM, CFU-Mix colony, points out its propagation to myeloid element, differentiation that facilitation is arranged; It can obviously improve the immunologic derangement of Induced Aplastic Anemia Mice, and its effect link is many-sided, and is different with immunosuppressant cyclosporin commonly used, and do not have the common toxic and side effects of immunosuppressant.
The invention has the advantages that: selecting ten crude drugs for use is that raw material carries out assembly, particularly this three flavors principal agent of Leptoradix Ginseng Rubra wherein, the Radix Astragali and Radix Rehmanniae Preparata merges utilization, QI invigorating, the kidney invigorating, the problem of enriching blood in the aplastic anemia treatment have been solved well, has the kidney warming benefit marrow, the unique effects of qi-supplementing, blood-engendering.The asthenia that can cure mainly the patient is deficient, oligospermia anemia, pallor is impractical, the empty fear of body is cold, have a dizzy spell, diseases such as the acid of waist knee joint is cold, cardiopalmus is weak, sexual impotence oligospermia, anorexia and loose stool.Confirm that through clinical observation its curative effect height, adaptability are strong, the total effective rate of treatment aplastic anemia obviously is better than existing Western medicine and similar Chinese medicine compound preparation, prescription up to 80%.And selected natural material does not have rare animal medical material, avirulence or limiting the use of property medical material, no valuable medicinal, the outer medical material of no grade III Standard, and each component meets the pharmaceutical control law regulation.Its co-action for treating aplastic anemia that organically combines, almost without any side effects.Simultaneously prepared and Chinese medicine need not to decoct, take with easy to carry, with low cost, greatly reduce total medical expense of patient, be easy to clinical application, have the wide development prospect.
In order to show the therapeutic effect of Chinese medicine of the present invention to aplastic anemia, the present invention is by the 4th criterion of therapeutical effect that national aplastic anemia academic conference is formulated in 1987, from being in hospital and blood special outpatient clinic selection case.Finished the collection of 80 routine clinical cases, random packet is observed, and wherein test group 50 examples are treated with Chinese medicine electuary of the present invention, and contrast I organizes 15 examples and treats with FUFANG ZAOFAN WAN, and contrast II group is treated with stanozolol.Test group 50 examples, male 31 examples, women 19 examples, 16～72 years old age, average 43.2 years old; Press the standard of Camitfa, aplastic anaemia 8 examples (comprising acute SAAI type 2 examples, chronic heavy type SAAI type 6 examples) wherein, chronic plain edition aplastic anemia 42 examples; The course of disease 3～42 months, average 19.6 months; Just control 22 examples, control 28 examples again.Contrast I organizes 15 examples (comprising SAAI type 4 examples), male 10 examples, women 5 examples, 21～68 years old age, average 39.6 years old; Contrast II organizes 15 examples (comprising SAAI type 4 examples), male 9 examples, women 6 examples, 18～69 years old age, average 41.8 years old.Three groups of patients are in aplastic anemia typing (heavy, plain edition) ratio, age, sex, the course of disease, control and reflect that all there is comparability (P＞0.05) aspects such as hemogram, bone marrow smear of state of an illness weight just, again.
Test group patient all takes Chinese medicine electuary of the present invention (entrusting the hospital preparation chamber to make electuary), and dosage: the adult takes 2 bags at every turn, and every bag 12 grams service once sooner or later.Contrast I group patient all takes FUFANG ZAOFAN WAN (its army's pharmacy company limited of Shaanxi Hao is produced), and dosage: the adult takes 9 at every turn, and every 1.8 gram is obeyed three every day.Contrast II group patient all takes stanozolol (Nanning Pharmaceutical Engerprise's production), dosage: the adult takes 2 milligrams at every turn, obeys every day three times.Treatment was a course of treatment with six months all.
Observation index: routine blood test adopts COULTERT-540 cytoanalyze electric-resistivity method to measure.The t lymphocyte subset group changes the employing indirect immunofluorescence and measures.Serum trilute (T
3), thyroxine (T
4), testosterone (T), hydrocortisone (F) changes uses measured by radioimmunoassay, presses the operation of test kit description method.Interleukin II (IL-2), soluble il-2 receptors (sIL-2R), interleukin (IL-3), r-interferon (IFN-r), the variation of a-tumor necrosis factor (TNF-a) all adopts the ELISA method to measure, and the strict test kit description method of pressing is operated.
Clinical test results is shown in table 1, table 2, table 3, table 4, table 5, table 6.
The clinical efficacy that table 1 is taken behind Chinese medicine of the present invention and compound recipe soap sulfone ball and the stanozolol compares
| Case load | Basic cure (%) | Alleviate (%) | Obviously progressive (%) | Invalid (%) | Total effective rate | |
| Test group contrasts 1 group and contrasts 2 groups | 50 15 15 | 4 examples (8%) 0 example, 0 example | 13 examples (26%) 2 example (13.33%) 2 example (13.33%) | 23 examples (46%) 4 example (26.67%) 5 example (33.33%) | 10 examples (20%) 9 example (60%) 8 example (53.33%) | 80％ 40％ 46.67％ |
As can be seen from Table 1, test group is cured substantially, alleviation and total effective rate all obviously be better than contrasting I group and contrast II group (P＜0.05 or P＞0.01).
The T cell subsets changes relatively before and after three groups of patient treatments of table 2
| Grouping | CD4(％) | CD4(％) | CD8(％) | CD4/CD8(％) | |
| The normal value test group contrasts 1 group and contrasts 2 groups | After preceding treatment is treated in the treatment back before treating after the treatment before the treatment | 64.2±6.8 54.2±6.6 62.9±7.1 51.1±7.7 57.4±8.2 56.3±6.8 58.1±8.1 | 40.2±5.1 37.6±4.2 41.3±5.3 37.4±5.2 36.8±6.4 36.9±6.1 37.4±7.6 | 25.2±4.5 31.6±8.3 25.4±3.9 30.9±7.6 30.6±7.9 29.6±8.8 30.1±6.8 | 1.80±0.44 1.28±0.38 1.79±0.42 1.21±0.32 1.20±0.41 1.25±0.29 1.24±0.25 |
As can be seen from Table 2, the variation of three groups of treatment front and back T cell subsets.CD before the test group treatment
4And CD
4/ CD
8Than the obvious reduction of normal value (P＜0.05 or P＜0.01), obvious rising is arranged after the treatment, approach normal value, with comparing difference before the treatment significance (P＜0.05 or P＜0.01) is arranged, and CD
8Cell has obvious rising (P＜0.05) than normal value before treatment.T cell subsets data and test group comparing difference that contrast I group and contrast II group patient measure before treatment are infinitely added to the fun, and also do not have significant change after the treatment.Test group treatment back CD
4And CD
4/ CD
8Obviously rise CD
8Obviously descend, point out Chinese medicine electuary of the present invention, remove CD by regulating body's immunity
8Cell suppresses hemopoietic, helps hemopoietic and recovers.
The variation comparison of T3, T4, F and T before and after three groups of patient treatments of table 3 (X ± S)
| Grouping | T3 (ng/ml) | T4 (ng/ml) | F (ng/ml) | T(ng/ml) | ||
| The man | The woman | |||||
| The normal value test group contrasts 1 group and contrasts 2 groups | After preceding treatment is treated in the treatment back before treating after the treatment before the treatment | 1.4±0.5 0.92±0.22 1.42±0.54 0.88±0.46 0.92±0.54 0.91±0.48 0.96±0.58 | 85±40 57±28 92±36 60±38 64±42 59±32 62±34 | 120±80 39±21 52±17 42±24 40±28 41±19 42±26 | 6.7±4 1.8±0.81 4.1±2.11 2.1±1.01 2.4±1.13 1.9±0.93 3.9±1.85 | 0.46±0.4 0.21±0.11 0.39±0.21 0.23±0.15 0.26±0.18 0.25±0.17 0.41±0.23 |
As can be seen from Table 3, three groups of patients serum T before treatment
3, T
4, T, F content all be lower than normal value.After treatment, test group patients serum T
3, T
4, T, F content all than the treatment before remarkable rising is arranged, difference has significance (P＜0.05); The level of T has remarkable rising behind the contrast II group patient treatment, and comparing difference with test group has significance (P＜0.05), may with androgen stimulate relevant, T
3, T
4, no significant change before and after the F treatment; Contrast I has no significant change before and after organizing every index treatment.
Table 4 three groups of patient IL-2, SIL-2R, IL-3, IFN-r, TNF-a change relatively
| Grouping | IL-2 | sIL-2R | IL-3 | IFN-r | TNF-a | |
| The normal value test group contrasts 1 group and contrasts 2 groups | After preceding treatment is treated in the treatment back before treating after the treatment before the treatment | 56.48±20.22 97.87±17.13 62.82±14.02 93.46±19.22 89.14±18.96 98.96±20.14 92.16±18.34 | 250±15 173.69±21.24 214.45±32.69 171.47±25.29 180.19±30.57 179.46±31.44 185.16±29.32 | 24.82±7.42 6.24±3.66 10.52±3.82 7.01±3.15 7.69±4.01 6.84±3.16 7.86±4.12 | 5.12±2.72 9.53±2.39 7.25±2.30 8.86±3.12 8.88±2.96 9.24±2.44 8.96±3.02 | 6.32±2.84 12.79±3.75 9.4l±2.97 12.18±4.12 11.98±4.38 13.14±3.96 12.82±3.46 |
As can be seen from Table 4, three groups of patients IL-2, IFN-r, TNF-a before treatment are significantly higher than normal value (P＜0.05), also are higher than normal value after the treatment; Significantly be lower than normal value (P＜0.01) before sIL-2R, the IL-3 treatment, also be lower than normal value after the treatment.But the IL-2 behind the test group 50 routine patient treatments, IFN-γ, TNF-a have remarkable reduction (P＜0.05) before the treatment, have obviously before sIL-2R, IL-3 treat and increase (P＜0.01), no significant change before and after contrast I group and contrast II group are treated.
Bone marrow BFU-E productive rate (individual/10 before and after three groups of patient treatments of table 5
5Variation BMMNC) (X ± S)
| Group | BFU-E | ||
| Before the treatment | After the treatment | ||
| Test group contrasts 1 group and contrasts 2 groups | 3.8±2.9 4.1±3.2 3.9±3.1 | The responder | The nonresponder |
| 23.9±20.3 12.4±11.7 13.6±12.8 | 6.2±4.6 6.1±5.2 5.8±4.9 | ||
Bone marrow cfu-gm productive rate (individual/10 before and after three groups of patient treatments of table 6
5Variation BMMNC) (X ± S)
| Group | CFU-GM | ||
| Before the treatment | After the treatment | ||
| Test group contrasts 1 group and contrasts 2 groups | 5.1±2.8 4.9±2.5 5.2±3.4 | The responder | The nonresponder |
| 18.2±22.1 7.8±4.4 8.2±12.8 | 4.6+2.9 4.8+3.0 3.9±23.6 | ||
From table 5, table 6 as can be seen, compare with normal value, bone marrow BFU-E and CFU-GM colony productive rate all significantly reduce (P＜0.01) before three groups of patient treatments, compare between these three groups, have comparability (P＞0.05).Treatment back test group responder's BFU-E colony productive rate is apparently higher than contrast I group and contrast II group (P＜0.05), and near normal value (P＞0.05); Test group responder CFU-GM colony productive rate is apparently higher than contrast I group and contrast II group (P＜0.01), but still be starkly lower than normal value (P＜0.05), this differs greatly relevantly with its different stage curative effect patient CFU-GM colony productive rate, does not obtain obvious curative effects person's (comprising obvious progressive person) bone marrow cfu-gm colony productive rate and recovers bad or seriously bad.Before three groups of nonresponder's bone marrow BFU-E and CFU-GM colony productive rates and the treatment relatively, no significant difference (P＜0.05).
All done inspections such as liver, renal function and electrocardiogram before and after three groups of patient treatments, clothes stanozolol person often has ALT to raise, decrement and add hepatoprotective after, ALT recovers normally gradually, other indexs all do not have change.With Chinese medicine electuary of the present invention and FUFANG ZAOFAN WAN therapist, all no abnormal change of liver, renal function and Electrocardioscopy illustrates that Chinese medicine electuary of the present invention has no side effect.
The specific embodiment
The Chinese medicine and the preparation technology thereof of treatment aplastic anemia of the present invention are described in further detail below in conjunction with specific embodiment:
Embodiment 1: take by weighing raw material (kilogram) by following weight proportion:
Leptoradix Ginseng Rubra 25 Radixs Astragali 8 Radix Rehmanniae Preparata 8
Semen Cuscutae 8 Cornu Cervi tablets 8 Carapax Et Plastrum Testudinis (processed) 8
Fructus Lycii 8 Fructus Psoraleaes 8 Radix Aconiti Lateralis Preparata 8
Cortex Cinnamomi 2.
Embodiment 2: take by weighing raw material (kilogram) by following weight proportion:
Leptoradix Ginseng Rubra 30 Radixs Astragali 9 Radix Rehmanniae Preparata 9
Semen Cuscutae 9 Cornu Cervi tablets 9 Carapax Et Plastrum Testudinis (processed) 9
Fructus Lycii 9 Fructus Psoraleaes 9 Radix Aconiti Lateralis Preparata 9
Cortex Cinnamomi 3.
Embodiment 3: take by weighing raw material (kilogram) by following weight proportion:
Leptoradix Ginseng Rubra 35 Radixs Astragali 12 Radix Rehmanniae Preparata 12
Semen Cuscutae 11 Cornu Cervi tablets 11 Carapax Et Plastrum Testudinis (processed) 11
Fructus Lycii 10 Fructus Psoraleaes 14 Radix Aconiti Lateralis Preparata 9
Cortex Cinnamomi 5.
Its preparation technology is as follows: by the weight proportion in the foregoing description Leptoradix Ginseng Rubra, the Radix Astragali, Radix Rehmanniae Preparata, Semen Cuscutae, Cornu Cervi tablet, Carapax Et Plastrum Testudinis (processed), Fructus Lycii, Fructus Psoraleae, Radix Aconiti Lateralis Preparata, ten raw material of Chinese medicine of Cortex Cinnamomi are decocted with water twice, the decocting that at every turn adds 7 times of raw material weights boiled 45 minutes, merged the filtrate of twice decoction.Then the filtrate that merges is concentrated into relative density and is 1.15 (temperature 90 ℃ time measure), adding ethanol, to contain the alcohol amount to the filtrate be 55%, and precipitate with ethanol reclaimed ethanol more than 24 hours, further concentrated filtrate to relative density is 1.24 (temperature 90 ℃ time measure), is cooled to room temperature and becomes paste.
Again above-mentioned paste is carried out drying and sterilization place 30 minutes under 100～110 ℃ temperature, dust and make loose powder.Add an amount of adjuvant, but fill becomes capsule.Or the dextrin that adds 2 times of its weight in above-mentioned paste makes soft material, this soft material crossed behind 10 mesh sieves dry under 70 ℃ temperature, takes out, and granulate promptly can be made into dissolved granule after 12 mesh sieves.Or the starch that adds 1 times of its weight in above-mentioned paste makes soft material, this soft material crossed behind 10 mesh sieves dry under 70 ℃ temperature, takes out, and tabletting promptly can be made into tablet.
Patients with Aplastic Anemia can be taken this product according to the dose size of doctor's advice.In general, for the dissolved granule of every bag 10 grams, adult's secondary every day, each two bags, the morning and evening warm boiled water, six months is a course of treatment.Diseases such as the bone marrow depression that causes for other refractory anemia and a variety of causes, cytopenia, this product also has goodish curative effect.
Claims (5)
1. Chinese medicine for the treatment of aplastic anemia, it is characterized in that: it is the medicament that is prepared from by following materials of weight proportions:
Leptoradix Ginseng Rubra 25～35 Radixs Astragali 8～15 Radix Rehmanniae Preparata 8～15
Semen Cuscutae 8～15 Cornu Cervi tablets 8～15 Carapax Et Plastrum Testudinis (processed) 8～15
Fructus Lycii 8～15 Fructus Psoraleaes 8～15 Radix Aconiti Lateralis Preparata 8～9
Cortex Cinnamomi 2～5.
2. the Chinese medicine of treatment aplastic anemia according to claim 1 is characterized in that: the weight proportion of said each raw material is:
Leptoradix Ginseng Rubra 25 Radixs Astragali 8 Radix Rehmanniae Preparata 8
Semen Cuscutae 8 Cornu Cervi tablets 8 Carapax Et Plastrum Testudinis (processed) 8
Fructus Lycii 8 Fructus Psoraleaes 8 Radix Aconiti Lateralis Preparata 8
Cortex Cinnamomi 2.
3. the Chinese medicine of treatment aplastic anemia according to claim 1 and 2 is characterized in that: said medicament is a said dosage form on any pharmaceutics.
4. the Chinese medicine of treatment aplastic anemia according to claim 3 is characterized in that: said medicament is electuary, tablet or capsule.
5. the preparation technology of the Chinese medicine of the described treatment aplastic anemia of claim 4, it is characterized in that: Leptoradix Ginseng Rubra, the Radix Astragali, Radix Rehmanniae Preparata, Semen Cuscutae, Cornu Cervi tablet, Carapax Et Plastrum Testudinis (processed), Fructus Lycii, Fructus Psoraleae, Radix Aconiti Lateralis Preparata, ten raw material of Chinese medicine of Cortex Cinnamomi are decocted with water twice by above-mentioned weight proportion, the decocting that at every turn adds 6～8 times of raw material weights boiled 30～60 minutes, merged filtrate twice; Concentrate then, precipitate with ethanol, be cooled to room temperature and become paste; Again the fill of dusting after the paste dried is become capsule, or the dextrin or the starch that add 1～2 times of its weight in paste makes soft material, at last soft material is sieved, drying, make electuary or be pressed into tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031254667A CN1274338C (en) | 2003-09-29 | 2003-09-29 | Traditional Chinese medicine for treating aplastic anemia and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031254667A CN1274338C (en) | 2003-09-29 | 2003-09-29 | Traditional Chinese medicine for treating aplastic anemia and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1602896A CN1602896A (en) | 2005-04-06 |
| CN1274338C true CN1274338C (en) | 2006-09-13 |
Family
ID=34658755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031254667A Expired - Fee Related CN1274338C (en) | 2003-09-29 | 2003-09-29 | Traditional Chinese medicine for treating aplastic anemia and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1274338C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101401905B (en) * | 2008-11-10 | 2011-01-26 | 陈燕 | Chinese medicinal composition for treating aplastic anemia |
| CN105726776A (en) * | 2016-03-03 | 2016-07-06 | 郑州大学 | Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy |
| CN107751491A (en) * | 2016-08-19 | 2018-03-06 | 张金莲 | Health protection tea, preparation method and the usage |
-
2003
- 2003-09-29 CN CNB031254667A patent/CN1274338C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1602896A (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1256133C (en) | Antifatigue Chinese medicine composition and its prepn process | |
| CN1294015A (en) | Medicine for treating thyroid enlargement and thyroidism | |
| CN1370585A (en) | Composite Chinese medicine prepn for treating type II diabetes | |
| CN102274417B (en) | Chinese prepared medicament for treating aplastic anemia | |
| CN1274338C (en) | Traditional Chinese medicine for treating aplastic anemia and its preparation process | |
| CN101249208B (en) | Proprietary Chinese medicine preparations for curing chronic emphraxis lung diseases | |
| CN1927315A (en) | Medicine for treating psoriasis mainly and its preparation method and use | |
| CN1202847C (en) | Diabetes treating medicine | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN101675961B (en) | A medicinal preparation for treating breast cancer and preparation method thereof | |
| CN1830477A (en) | Medicine for treating woman deficiency of blood gynecological and its preparation method | |
| CN1287836C (en) | Chinese medicinal powder for treating diabetes and its production method | |
| CN1186036C (en) | Diabetes treating medicine and its prepn | |
| CN1256963C (en) | Antifatigue medicine and its preparation method | |
| CN1840049A (en) | Medicine for treating diabetic nephropathy | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN1428166A (en) | Chinese medicine composition for curing AIDS and its preparation mehtod | |
| CN1634541A (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN1064249C (en) | Traditional Chinese medicine for indication nearsight | |
| CN1140292C (en) | Medicine for increasing leucocyte and its preparation | |
| CN1210049C (en) | Chinese medicine composition for treating diabetes | |
| CN1562163A (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN1088801A (en) | Chinese patent medicine Jinguanpian tablets and the method for making thereof of treatment insensitive impediment, particularly RA and AS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060913 Termination date: 20170929 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |